**Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry** This study collects information on patients taking special medicines called anti-amyloid monoclonal antibodies (mAbs). These medicines aim to help people with Alzheimer's disease, a brain illness that affects memory and thinking. Recently, two mAbs, lecanemab and donanemab, have shown good results in trials. The study is run by Georgia Memory Net, which helps doctors understand how well these medicines work in real life. *Important Points:* - You must be between 50-90 years old with mild memory problems to join. - Patients will be observed during their treatment as per FDA guidelines. - Participants need to have a caregiver for follow-up visits and agree to specific tests and MRI scans. Before joining, ensure you don't have conditions like severe heart issues, uncontrolled diabetes, or recent serious infections. If you're breastfeeding or have severe allergies, you might not be eligible. Always talk to your doctor to see if joining is right for you.